Seoul National University

Snu Rdb Foundation

Korea Research Institute of Bioscience and Biotechnology

Industry-Academic Cooperation Foundation Gyeongsang National University

Korea Institute of Bioscience and Biotechnology

Industry-Academic Cooperation Foundation

Jung Weon Lee

Ki Hun Park

Hyung Won Ryu

Young Bae Ryu

Eunmi Kim

Se Mi Kim

Sin-Ae Lee

Soo Hyun Kim

Hye Jin Kim

Sei-Ryang Oh

Doo-Young Kim

Jung-hee Kim

Sangku Lee

In Pyo Choi

Joongku Lee

Sang Jick Kim

Hyeong-Kyu Lee

InPyo Choi

Eun-Ah Kim

Dongjoon Ko

Eun Ae Shin

Seo Hee Nam

Junghwa Yoon

HyeMi Ahn

Hye Jin Min

Jin Myeong Song

JiHye Ryu

Min Kyung Kang

Kyungseop Ahn

Su-Yong Choi

Soon-Ja Choi

Ho-Jae Lee

Jung-Hee Kim

Ji Hye Ryu

The present disclosure relates to TM4SF5-specific humanized antibodies and uses thereof.

TM4SF5-targeting humanized antibody and use thereof

The present invention relates to an immunosuppressant comprising TSAHC or a pharmaceutically acceptable salt thereof as an active ingredient. TSAHC treatment suppressed the expression and secretion of cytokines/chemokines such as IL6, IL1β, TNFα, CXCL1, CXCL2, CXCL3, CXCL6, CXCL8, CCL2, CCL5, CCL20, CXCL10 and CCR10 according to the expression of TM4SF5 gene and protein, and the cytokines or chemokines mediated by the expression of TM4SF5 induced abnormalities in the inflammatory response and metabolic function of liver tissues, hepatic epithelial cells and macrophages, and correlated with liver tissue damage and immune cell recruit in TM4SF5 transgenic animals. Therefore, a composition comprising TSAHC or a pharmaceutically acceptable salt thereof as an active ingredient can be effectively used as an immunosuppressant.

Immunosuppressant comprising TSAHC or a pharmaceutically acceptable salts thereof as an active ingredient

The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody.

Monoclonal antibody which is specifically bound to TM4SF5 protein and use thereof

The present invention relates to a method for screening an anticancer compound and an anticancer compound screened using the method, and more particularly, to a method for screening an anticancer compound, the method comprising: culturing cancer cells expressing the oncogenic protein transmembrane 4 L6 family member 5 (TM4SF5), expressed as the polypeptide of SEQ ID NO: 2, treating the cancer cells with an anticancer candidate, and determining that the anticancer candidate is an anticancer substance when the candidate exhibits antagonistic activity against tumor formation and metastasis based on several events through the molecular mechanism of TM4SF5. The present invention also relates to chalcone compounds screened to have anticancer activity using the method, and an anticancer composition comprising the compound as an effective ingredient.

Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds

A composition for diagnosing, treating, and preventing liver disease, more particularly a composition for diagnosing liver disease comprising a material for measuring the grade of TM4SF5 (transmembrane 4 L six family member 5 or four-transmembrane L6 superfamily member 5) protein, a kit for diagnosing liver disease comprising the composition, a method for providing information necessary for diagnosing liver disease composed of the following steps: measuring the level of TM4SF5 protein and the expressions and phosphorylations of TM4SF5 expression related signaling proteins; and comparing the measured levels with those of the normal control, a method for screening a material for treating liver disease, and a composition for treating or preventing liver disease comprising a material inhibiting TM4SF5 protein expression or the expressions and phosphorylations of TM4SF5 expression related signaling proteins.

Composition for diagnosing, treating, and preventing liver disease

The present invention relates to an anoikis-inducing agent comprising aextract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. Theextract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

[object Object]

Growing community of inventors

Seoul, South Korea

Jung Weon Lee